ARRY-520 Shows Encouraging Early Results For Relapsed And Refractory ... The Myeloma Beacon In addition, most patients had undergone an autologous stem cell transplant (81 percent in group 1 and 89 percent in group 2). During the course of the study, every patient received 1.5 mg/m2 of ARRY-520 on days 1 and 2 every two weeks. Additionally ... |
